IN THE SPECIFICATION:

Please further amend the first paragraph on page 2, line 6 to page 4, line 9, as follows:

(Currently amended) According to one aspect of the present invention there is provided an inhibitor of ras farnesylation of Formula I



wherein:

R^1 is selected from H; -C_{1-4}alkyl; -CO-C_{1-4}alkyl; -CO-O-C_{1-4}alkyl; -CO-O-C_{2-4}alkenyl; -C_{1-4}alkylene-$CONR^4R^5$ (wherein R^4 and R^5 are independently selected from H and C_{1-4}alkyl); -C_{1-4}alkylene-$COOR^6$ (wherein R^6 is selected from H and C_{1-4}alkyl); -C_{1-3}alkylene-Ph and -CO-O$(CH_2)_n$Ph wherein the phenyl groups in -C_{1-3}alkylene-Ph and -CO-O$(CH_2)_n$Ph are optionally substituted by R^a and/or R^b and R^a and R^b are independently selected from C_{1-4}alkyl, halogen, hydroxy, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, amino, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkanoylamino, nitro, cyano, carboxy, carbamoyl, C_{1-4}alkoxycarbonyl, thiol, C_{1-4}alkylsulfanyl, C_{1-4}alkylsulfinyl,C_{1-4}alkylsulfonyl and sulfonamido; and n=0-4;

R^2 is selected from H; -C_{1-4}alkyl; -COC_{1-4}alkyl; and -$COOC_{1-4}$alkyl; and -C_{1-3}alkylene-Ph optionally substituted on the phenyl ring by R^a and/or ~~and or~~ R^b;

R^3 is selected from H; OH; CN; CF_3; NO_2; -C_{1-4} alkyl; -C_{1-4}alkylene-R^7; -C_{2-4}alkenylene-R^7; -C_{2-4}alkynylene-R^7; R^7; OR^7 (where R^7 is selected from phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R^7 is optionally substituted by R^a and/or R^b);

C_{2-4}alkenyl; halogen; -$(CH_2)_yCOOR^8$ (where y = 0-3 and R^8 represents H, C_{1-4}alkyl, or C_{2-4}alkenyl); -$CONR^9R^{10}$ (where R^9 and R^{10} independently represent H, C_{1-4}alkyl, C_{2-4}alkenyl, -O-C_{1-4}alkyl, -O-C_{2-4}alkenyl or -C_{1-3}alkylenePh (wherein Ph is optionally substituted by R^a and R^b as hereinabove defined); -$CON(R^{11})OR^{12}$ (where R^{11} and R^{12} independently represent H, C_{1-4}alkyl or C_{2-4}alkenyl);

a group of Formula II: -$CONR^{13}$-$CR^{13a}R^{14}$-$COOR^{17}$, (where R^{13} and R^{13a} are independently H or C_{1-4}alkyl, R^{17} is H or C_{1-6}alkyl, R^{14} is selected from the side chain of a lipophilic amino acid, carbamoylC_{1-4}alkyl, N-(monoC_{1-4}alkyl)carbamoylC_{1-4}alkyl and N-(diC_{1-4}alkyl)carbamoylC_{1-4}alkyl, the group of Formula II having L or D configuration at the chiral alpha carbon in the corresponding free amino acid; a lactone of formula:



;

C_{1-4}alkyl monosubstituted on carbon with =N-OH;

a group of Formula -X-R^{15} (where X is selected from O, CO, CH_2, S, SO, SO_2 and R^{15} is selected from C_{1-6}alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R^{15} is optionally substituted by R^a and/or R^b;

p is 0-3 in which R^3 values can be the same or different;

G is a linking moiety selected from the following groups written from left to right in Formula I:



(wherein the piperazine and perhydro-1,4-diazepine rings are optionally substituted); -CO-NR^{16}-; -CH_2.NR^{16}- ; -CH_2S-; -CH_2O-; -CH_2-CHR^{16}; -CH=CR^{16}-; -CH_2NR^{16}-T-; -CH_2NR^{16}-SO_2-; -CH_2-NR^{16}-CO-T'-; -CO-NR^{16}-T-; -CH_2S-T-; -CH_2O-T- (where R^{16} is selected from H, C_{1-4}alkyl, C_{1-4}alkylene-Z, -CO-C_{1-4}alkylene-Z, -CO-C_{1-6}alkyl, -COZ, Z and

Z is selected from -O-C_{1-4}alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R^{16} is optionally substituted by R^a and/or R^b as hereinabove defined;

where, T represents -$(CH_2)_m$- where m is 1-4 and T is optionally monosubstituted with any value of R^{16} other than H; and

where T^1 represents -$(CH_2)_{m^1}$- wherein m^1 is 0-4 and T^1 is optionally monosubstituted with any value of R^{16} other than H);

A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N & S;

or a -S-S- dimer thereof when R^2=H; or a N-oxide thereof;

or a pharmaceutically acceptable salt, prodrug or solvate thereof.